Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1675
This examiner grants 76% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18017041 | CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY | Non-Final OA | Novo Nordisk A/S |
| 18518981 | Treatment of Glaucoma by Neuroprotection | Non-Final OA | The Regents of the University of California |
| 17442831 | COMPOSITIONS AND METHODS OF TREATING AND PREVENTING SYSTEMIC COMPLICATIONS OF ACUTE ILLNESS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17795797 | THERAPEUTIC USES OF DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18280186 | APPLICATION OF APOPTOSIS INHIBITOR 5 (API5) FOR EPITHELIAL RESTITUTION | Non-Final OA | New York University |
| 18011363 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING COGNITIVE DYSFUNCTION DISEASE, COMPRISING PEPTIDE HAVING SYNAPTIC PLASTICITY CONTROL FUNCTION | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 18652429 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | Final Rejection | Sanford Burnham Prebys Medical Discovery Institute |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy